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Antiviral Drug-Resistant HBV: Standardization of
Nomenclature and Assays and Recommendations for
Management
Anna S. Lok,1 Fabien Zoulim,2 Stephen Locarnini,3 Angeline Bartholomeusz,3 Marc G. Ghany,4 Jean-Michel Pawlotsky,5
Yun-Fan Liaw,6 Masashi Mizokami,7 and Carla Kuiken,8 and the Hepatitis B Virus Drug Resistance Working Group
Substantial advances have been made in the treatment of chronic hepatitis B in the past
decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon
and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after
withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases,
indefinite treatment with increasing risk of development of drug resistance. Antiviral resis-
tance and poor adherence are the most important factors in treatment failure of hepatitis B.
Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance,
and to define genotypic, phenotypic, and clinical resistance to NA therapy. (HEPATOLOGY
2007;46:254-265.)
1. Introduction
Substantial advances have been made in the treatment of
chronic hepatitis B in the past decade. Approved treat-
ments for chronic hepatitis B have expanded from just
one agent to a total of six agents: standard interferon
(IFN), pegylated IFN, lamivudine (LAM), adefovir
dipivoxil (ADV), entecavir (ETV), and telbivudine
(LdT). In addition to the four approved nucleos(t)ide
analogues (NAs) for chronic hepatitis B, tenofovir
disoproxil fumarate (TDF), the prodrug of tenofovir
and the coformulation of TDF and emtricitabine, ap-
proved treatments for human immunodeficiency virus
(HIV) infection, have activity against hepatitis B virus
(HBV).
Although NAs are more convenient than IFN-based
therapies and have fewer side effects, sustained viral sup-
pression is usually not achieved after withdrawal of a 48-
week course of NA therapy, necessitating long, and in
many cases, indefinite treatment. Unfortunately, a long
duration of NA treatment is associated with an increasing
risk of development of drug resistance. Antiviral resis-
tance and poor adherence are the most important factors
in treatment failure. Thus, there is a need to standardize
nomenclature relating to HBV antiviral resistance, and to
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define genotypic, phenotypic, and clinical resistance to
NA therapy. In this review, we propose definitions of
terminologies, briefly describe available methods for de-
tecting and quantifying drug resistance, and discuss the
interpretation of drug resistance data and its current and
future application in clinical practice.
(a) Clinical Classification of Antiviral Resistance
At the 2006 National Institutes of Health Workshop
on HBV, standardized definitions of response to antiviral
therapy were proposed (Table 1).1 More detailed clarifi-
cation of terminologies that are commonly used in de-
scribing antiviral resistance is provided here. A sensitive
and specific HBV DNA assay with a wide dynamic range
of quantification, calibrated to express results in WHO
international units per ml (IU/ml), should be used to
quantify serum HBV DNA levels prior to treatment, to
assess response, and to detect virologic breakthroughs.
(i) Primary Antiviral Treatment Failure (or Non-
response). Primary nonresponse is defined as the inability
of NAs to reduce serum HBV DNA by 1 log10 IU/ml after
the first 6 months of treatment. This definition was chosen as
it exceeds variability in HBV DNA assays and reflects a true
virologic response but a decrease in HBV DNA level by 1
log10 IU/ml is not a meaningful clinical response. Primary
nonresponse may be due to factors related to the host, virus,
or drug. Polymorphisms in enzymes involved in converting
prodrugs to the active compounds or in phosphorylating
NAs to their triphosphates (active moiety) may contribute to
primary nonresponse.2,3 Certain viral strains may be less sus-
ceptible to one or more antiviral therapies as suggested by a
recent case report on primary nonresponse to adefovir.4 Po-
tency and dose of the antiviral therapy may also be impor-
tant. For example, the approved dose of adefovir (10 mg
daily) is not as potent as higher doses and may be the most
important factor in the high rate of primary nonresponse to
adefovir.5
Monitoring for primary nonresponse is important be-
cause a high residual viral level after the first 6-12 months
of therapy has been demonstrated to be associated with
increased risk of antiviral resistance.6-8
(ii) Secondary Antiviral Treatment Failure (or Vi-
rologic Breakthrough). Virologic breakthrough, which
is usually associated with drug resistance, is defined as a
1 log10 IU/ml increase in serum HBV DNA level from
nadir in two consecutive samples 1 month apart in pa-
tients who have responded and have been compliant with
antiviral medication(s).9,10 Confirmation of the increase
in serum HBV DNA in a second sample is not necessary
in patients with accompanying flare in aminotransferase
level. Serum HBV DNA levels tend to be low initially
because most antiviral-resistant HBV mutants have
decreased replication fitness compared to wild-type
HBV.11,12 However, compensatory mutations that can
restore replication fitness frequently accumulate during
continued treatment leading to viral rebound — progres-
sive increase in serum HBV DNA level that may exceed
pretreatment value.10
(iii) Biochemical Breakthrough. Biochemical break-
through is defined as elevation in serum aminotransferase
level during treatment in a patient who had achieved ini-
tial normalization. Serum aminotransferases may remain
normal for a few weeks or a few years after virologic break-
through. Biochemical breakthrough often coincides with
a viral rebound, in some cases a marked increase in ami-
notransferases occur resulting in a hepatitis flare (amino-
transferase 5 times the upper limit of normal) and rarely
hepatic decompensation.13,14
2. Definition of Genotypic Antiviral
Resistance
A fundamental issue in antiviral resistance is the crite-
ria for defining drug-resistant mutations. When a muta-








Increase in serum HBV DNA by 1 log10 above nadir on 2 occasions 1 month apart, while on treatment, after
achieving initial response in a medication compliant patient
Biochemical breakthrough Elevation in serum alanine aminotransferase (ALT) while on treatment, after achieving normalization in a medication
compliant patient
Genotypic resistance Detection of viral populations bearing amino acid substitutions in the reverse transcriptase region of the HBV genome
that have been shown to confer resistance to antiviral drugs in phenotypic assay, during antiviral therapy. These
mutations are usually detected in patients with virologic breakthrough but they can also be present in patients with
persistent viremia and no virologic breakthrough.
Phenotypic resistance Decreased susceptibility of an HBV polymerase to an antiviral treatment in vitro
Cross resistance Decreased susceptibility to more than one antiviral drug conferred by the same amino acid substitution or
combination of amino acid substitutions
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tion occurs during replication, it results in a nucleotide
substitution. The substitution can be synonymous (not
associated with an amino acid change) or non-synony-
mous (associated with an amino acid change). A resistance
mutation induces an amino acid change that decreases the
sensitivity to an antiviral drug.
Genotypic antiviral resistance designates the pres-
ence of unique nucleotide and corresponding deduced
amino acid mutations in the drug target gene (the HBV
polymerase gene in the case of HBV treatment with NAs)
that have been previously demonstrated to be associated
with antiviral resistance. Ideally, to identify potential ge-
notypic resistance, the nucleotide and deduced amino
acid sequence of HBV isolated from the patient during
virologic breakthrough should be compared to the se-
quence of HBV isolated from a pretreatment sample from
the same patient. When pretreatment samples are not
available for analysis, sequence data at the time of viro-
logic breakthrough should be compared to consensus
published sequence(s) of the same HBV genotype.
Primary drug resistant mutations cause an amino
acid substitution that result in reduced susceptibility to an
antiviral agent while secondary compensatory muta-
tions cause amino acid substitutions that restore func-
tional defects in viral polymerase activity (i.e., replication
fitness) associated with primary drug resistance.
For example, primary lamivudine resistance associated
changes occur at codon 204 and result in amino acid
changes within the tyrosine-methionine-aspartate-
aspartate (YMDD) motif - rtM204V/I (methionine to
valine or isoleucine substitution). These changes cause
a greater than 100-fold decrease in susceptibility to
lamivudine in phenotypic assays. The most common
compensatory mutation associated with lamivudine re-
sistance, rtL180M (leucine to methionine substitu-
tion) restores replication fitness of HBV polymerase
that harbors the rtM204V/I mutation.12
While no true competitive replication fitness assay has
been developed, the current in vitro assays can determine
relative replication yield phenotype to compare HBV
DNA encoding specific mutations to the reference, con-
sensus, or wild-type genetic framework.15,16 For example,
HBV replication competent clones encoding the rtV173L
(valine to leucine substitution)  rtL180M  rtM204V
were demonstrated to have an increased replication yield
phenotype but no change in sensitivity to lamivudine rel-
ative to HBV clones encoding rtL180M  rtM204V.17
Therefore, the rtV173L change should be considered a
compensatory mutation in the HBV DNA genome.
New HBV nucleotide and corresponding deduced
amino acid mutations detected in 2 or more patients un-
dergoing the same antiviral treatment with virologic
breakthrough despite medication compliance can be de-
fined as a “putative” resistance mutation, and given a pro-
visional status until confirmatory in vitro phenotype
testing can be performed. Thus, there need to be sufficient
data to determine if the selection of a particular nucleo-
tide mutation and deduced amino acid change is unique
to the antiviral selection pressure. In addition, the muta-
tion should not be detected in patients who have contin-
ued to respond to the same antiviral treatment or be
present prior to treatment using readily available assays
that detect mutants comprising 5% of the viral popu-
lation. Although antiviral-resistant mutations can be de-
tected using ultra-sensitive assays (see below) from
pretreatment samples and/ or before virologic break-
through, the likelihood of HBV encoding the mutation(s)
as the dominant quasispecies in pretreatment samples
without selection pressure is very low.
Confirmation of genotypic resistance is based on 2
methods: (a) in vitro phenotypic analysis and (b) virtual
phenotypic analysis which is the correlation of patient
treatment and response data with HBV sequence data.
(i) In Vitro Phenotypic Analysis. In vitro phenotypic
assay is the “gold standard” to confirm genotypic antiviral
resistance. Unfortunately, the methodology is time con-
suming and labor intensive due to the lack of a convenient
cell culture system and the need to use specific HBV rep-
lication competent clones. In addition, multiple substitu-
tions or sequences elsewhere in the HBV genome may
influence the result.
(ii) Virtual Phenotypic Analysis: Correlation of Pa-
tient Treatment and Response Data with HBV Se-
quence Data. This method relies on relational HBV
databases with both clinical, virological, and HBV se-
quence information that are integrated and analyzed sta-
tistically via linkage. 18 Large numbers of patients with
virologic breakthrough during treatment are required.
The input clinical and sequence data are compared to the
database to determine the best match and most likely
treatment response.
(a) Nomenclature
After the initial detection and reporting of antiviral
resistance, there was confusion in the naming of drug-
resistant mutations as the HBV genotypes vary in
genomic length. In 2001, Stuyver and colleagues over-
came this problem by dividing the HBV polymerase into
four different functional units and re-numbering each
functional unit.19 The reverse transcriptase (rt) region of
the polymerase gene is common for all genotypes. Muta-
tions within this region are prefixed with the letters rt
followed by the original deduced amino acid, the codon
number relative to the start of the rt region, followed by
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the deduced amino acid derived by the mutation. For
example, the primary LAM resistance associated changes
are defined as rtM204I and rtM204V using this nomen-
clature (substitution of methionine at codon 204 in the
reverse transcriptase region of the HBV polymerase gene
for isoleucine or valine). These LAM-resistant changes
should not be referred to as “a YMDD mutant” as only
the methionine of the conserved YMDD locus is changed.
(b) Technical Issues Associated with the Genotypic
Identification of New Antiviral Resistance
Mutations
The accepted standard for characterizing the sequence
of HBV polymerase in order to identify known or new
resistance mutations is double-stranded (or bi-direc-
tional) sequencing of the PCR amplified product. Reports
on newly identified antiviral resistance mutations should
include changes in nucleotide and amino acid sequences
in the reverse transcriptase region of the HBV polymerase
as well as any deduced amino acid change in the overlap-
ping envelope reading frame and the sequences should be
deposited in Genbank. Where more than one nucleotide
change (i.e., mixed HBV population) is detected at the
same position, both deduced amino acids using the Inter-
national Union of Pure and Applied Chemistry (IUPAC)
codes should be listed. For example, a mixed population
of wild type sequence and LAM-resistant mutation would
be reported as rtM204M/V and the corresponding
change from isoleucine at codon 195 of the overlapping
HBV surface protein to a mixture of methionine and
isoleucine indicated as sI195M/I.
(c) Methods to Detect Genotypic Resistance
Mutations
Assays available to identify resistance mutations in-
clude direct sequencing of PCR products, PCR amplifi-
cation followed by sequence analysis of multiple clones
derived from the amplicon, real time PCR formats with
specific probes including allele specific PCRs, hybridiza-
tion methods such as the line probe assay, restriction frag-
ment length polymorphism (RFLP), and more recently
matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS) based restriction
fragment mass polymorphism (RFMP) which can detect
mutants that comprise 1% of the viral quasispecies.20,21
The more sensitive assays can detect HBV DNA encoding
the resistance mutations that represent 5%-10% of the
entire HBV quasispecies enabling earlier identification of
patients with genotypic resistance mutations prior to or at
the time of virologic breakthrough. However, the utility
of ultra-sensitive assays that can detect mutants compris-
ing 1% of the viral population in predicting drug resis-
tance remains to be determined.
(i) Direct PCR Sequencing. Direct PCR sequencing is
the least sensitive in detecting minor populations of resistant
mutants as HBV DNA encoding the resistance mutations
needs to reach approximately 20% of the total HBV quasi-
species pool before these mutations can be observed. Direct
sequencing is also not amenable to high throughput screen-
ing. However, direct PCR sequencing does allow for all mu-
tations to be identified, including additional potential
compensatory mutations and new undefined mutations. For
new therapies, or the identification of new mutations associ-
ated with resistance to existing therapies, in vitro phenotypic
confirmatory assays are required.
(ii) RFLP Analyses. RFLP analyses can detect viral
mutants that constitute as little as 5% of the total viral
population.22 However, separate sets of endonuclease re-
actions must be designed specifically for each mutant of
interest. Some mutations result in a new restriction site
and RFLP is therefore an easy method; some other muta-
tions destroy a restriction site and in this case RFLP anal-
ysis should be used with caution as lack of enzyme
digestion may be due to loss of a restriction site or tech-
nical problems with the assay. RFLP analysis may not be
possible for all resistant mutations as endonucleases spe-
cific for such sequences may not exist.
(iii) Reverse Hybridization Assay LiPA DR. The
commercially available reverse hybridization assay LiPA
DR (Innogenetics, Belgium) can detect single nucleotide
mismatches and the assay contains a series of short mem-
brane-bound oligonucleotide probes. LiPA assays can de-
tect emerging viral resistance when HBV encoding the
resistance mutations constitute 5% or more of the total
viral population.21,23-25 Their major limitation is that new
sets of specific probes are required for every mutant and
due to genotype variability a number of probes may be
required to detect a single nucleotide change.
(iv) Sequencing with Microchip-Based Technology.
Sequencing with microchip-based technology using oli-
gonucleotide microarrays may be used to detect “new”
mutants. This technology is expensive and not widely
available.26
(v) MALDI-TOF MS. MALDI-TOF MS is based on
mass spectrometric analysis of small DNA fragments con-
taining sites of variation.20 This assay has been shown to
be very sensitive and can detect mutants that constitute
only 1% of the viral population.21 However, a new set of
primers must be designed to detect each new mutation
and access to mass spectrometer is required.
(vi) Single Genome Sequencing. Single genome se-
quencing has been used in studying antiviral-resistant
HIV mutations.27,28 This method is tedious and does not
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provide information on the absolute frequency of the mu-
tation. In addition, given the high rate of spontaneous
mutations during HBV replication, the clinical signifi-
cance of mutants that may be present in 0.1% of the
viral population is uncertain.
With four approved NAs for chronic hepatitis B and
several more in development, designing assays that would
permit detection of all the mutations known to confer
resistance to these medications is increasingly difficult.
Any of the above assays can be used for research as long as
the method is specified in the report. The most com-
monly used methods in clinical practice include direct
sequencing and line probe assay.
3. Definition of In Vitro Phenotypic
Antiviral Resistance
Demonstration that a given amino acid substitution
confers resistance is based on the use of phenotypic assays
that demonstrate in vitro a reduced susceptibility of a
replication competent clone with that substitution to an
antiviral agent against HBV as compared to a replication
competent clone with the “wild-type” sequence (without
the substitution). In vitro phenotype testing is based on
the determination of changes to the effective concentra-
tion of the drug required to inhibit 50% of the target
(EC
50
or IC50) relative to the “wild-type” reference HBV.
Clinically, antiviral drug resistance is commonly de-
scribed as high- (100-fold increase), intermediate- (10-
99–fold increase) or low-level (2-9–fold increase) (Table
2). Unfortunately, such ranking of drug resistance as de-
termined from in vitro phenotypic tests does not readily
translate to what is observed clinically. For example, a
small decrease in in vitro ADV susceptibility (2-9–fold
increase in EC50) may confer resistance in vivo.
(a) Methods Used for Phenotyping
Antiviral susceptibility testing involves assaying the ac-
tivity of the polymerase enzyme or of HBV replication.
These methods are time consuming and require a high
level of technical expertise.29
(i) Phenotyping Based on Enzymatic Assays. Cur-
rently, the only assays for the study of HBV polymerase
activity are based on the polymerase expressed in insect
cells using a baculovirus vector, and on HBV polymerase
expression in purified HBV nucleocapsids.30,31 A cell-free
assay has been developed for duck hepatitis B virus
(DHBV) but HBV polymerase gene contains a large in-
sert not present in DHBV or other hepadnavirus poly-
merase genes, and this insertion may affect the
interpretation of phenotype testing results.32,33
(ii) Phenotyping Based on Transient Transfection
of Hepatocyte-Derived Cell Lines. Two approaches
based on transient transfection have been used for phe-
notyping. The first relies on site-directed mutagenesis
to generate point mutations that may be associated
with drug resistance in recombinant, well-character-
ized “laboratory” HBV replication competent clones.
This approach may be an advantage for research pur-
poses as specific mutation(s) can be determined as be-
ing or not being associated with reduced antiviral
susceptibility. However, in some instances multiple
mutations and/or the broader genetic framework of the
HBV DNA from a patient may be required to confer
antiviral resistance. The second method relies on am-
plified full-length HBV genomes from clinical isolates
(rather than laboratory generated mutants).16 How-
ever, as a number of mutations and/ or clonal variants
may be present; the effect may be a culmination of all
the changes in the reverse transcriptase region as well as
other aspects of the HBV genome sequence unique to
that particular patient and not simply the effect of one
particular mutation.
(iii) Phenotyping Based on Transduction of Recom-
binant Baculovirus/HBV into Hepatocyte-Derived
Cell Lines. Recombinant baculovirus/HBV has also
been used for phenotyping.15,34 In this system, HBV rep-
Table 2. In vitro and in vivo Significance of Antiviral-Resistant Mutations
Lamivudine Clevudine Telbivudine Entecavir Adefovir Tenofovir
HBV -Fold Resistance -Fold Resistance -Fold Resistance -Fold Resistance -Fold Resistance -Fold Resistance
Wild-type 1 1 1 1 1 1
M204l 100 a, h 100 a 4 d 1 d 1-8a, b, c 1d
L180M  M204V 100 a, h 100 a NA 5-6 e, f 1-4a, b, c 3-6 f, g
A181 T/V 1-2 d, h NA 5-6 d 1-4 d 1-3 d 1 d
N236T 1 f, h NA 3 d 1f 3 f 5 f
I169T  V173L  M250V 1000 d, h NA 1000 d 700 e 1 d 1d
T184G  S202l * 1000 d, h NA 35 d 700 e 2 d 6 d
A194T NA NA NA NA NA 2 h
* ( L180M  M204I/V); NA  Not Available
2 – 9 fold 3 no or low level of resistance; 10 – 99 fold 3 medium level of resistance; 100 fold 3 high level of resistance
References: a Chin et al.53; b Delaney et al. (2001)34; c Ono et al.73; d Sozzi et al.74; e Tenney et al.47; f Brunelle et al.48; g Sheldon et al.58; h Delaney et al. (2006).59
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lication is driven by endogenous promoters and therefore
studies on relative replication yield phenotype can be per-
formed; however, this technique is tedious.15
(iv) Phenotyping Based on Continuous Cell Lines
Containing Stably-Integrated HBV Genomes. Stably-
transfected HBV-expressing cell lines have been created
specifically for the investigation of drug resistance.35 The
advantage of using stable cell lines for phenotype testing is
the ability to perform cross-resistance testing in a consis-
tent environment but a new cell line needs to be created
for each new mutant.36 The integration site of HBV DNA
within the cellular chromosome may affect HBV replica-
tion and cellular function; therefore, these cell lines can-
not be used to determine the relative replication efficiency
of HBV encoding the antiviral resistance mutations.
4. HBV Resistance Databases and Virtual
Phenotyping
Virtual Phenotyping involves assigning a phenotype
for a clinical isolate based on the correlations from large
databases containing genotypic, phenotypic, and clinical
information.
The analytical program searches linked databases for
the best matches among sequences known to confer par-
ticular phenotypes. Virtual phenotyping should be con-
sidered as an adjunct and not a substitute to in vitro
phenotype testing.
The first program developed to correlate HBV patient
clinical, virological, and HBV sequence information
is SeqHepB http://www.seqvirology.com/genome7/
index.htm. Registered users can access the program on-
line, and input either genomic (nucleic acid) or amino
acid sequences of clinical HBV isolates for analysis.
SeqHepB defines all amino acid variations within the
input sequences compared to reference sequence(s) of
the same genotype as mutations37 and correlate the
results with a database of HBV genotype and pheno-
type data and clinical histories. Various data mining
algorithms and functions are being developed that fa-
cilitate rapid and efficient identification of new mark-
ers of drug resistance. One such function includes the
localization of deduced amino acid changes on a mo-
lecular model of the HBV reverse transcriptase.38 This
function can provide insights into the significance of a
mutation in relation to antiviral drug resistance and
potential mechanism for antiviral resistance.38,39
The European Network of Excellence on antiviral drug
resistance management, ViRgil, is also developing a data-
base using a common clinical record form and a central-
ized virology laboratory.
The Hepatitis Virus Database (HVDB) in Japan is
open to the public http://s2as02.genes.nig.ac.jp. It is up-
dated 4 times a year using the newest release of DDBJ
(DNA Data Bank of Japan) and currently contains
10,892 HBV entries. The HVDB is mainly geared to-
wards phylogenetic analyses.
If properly designed, a database can greatly facilitate
the tracking of known resistance mutations and the devel-
opment of new ones. It would also allow more fundamen-
tal research on mutation interactions, epidemiological
studies on the spread of resistant mutations, and system-
atic study of the risk factors associated with the emergence
of resistant mutations and the clinical outcomes of pa-
tients with antiviral resistance. Additional advantages are
an easily accessible overview of known resistance muta-
tions for treating physicians and timely dissemination of
information on resistance profile changes.
5. Mutations Associated with Antiviral
Resistance
The incidence of genotypic resistance is related to viral
(pretreatment serum HBV DNA level, pre-existing anti-
viral-resistant mutations), host (immune status, pharma-
codynamics), and treatment characteristics (potency,
genetic barrier to resistance [number of mutations re-
quired to produce a marked decrease in susceptibility to
the antiviral drug], and duration of treatment). The inci-
dence of genotypic resistance also varies with the sensitiv-
ity of the methods used for detection of resistant
mutations (see section 2: Definition of Genotypic Antivi-
ral Resistance) and the patient population being studied.
Thus, clinical studies have varied from testing samples
from all patients with detectable serum HBV DNA by
PCR assay using sensitive methods such as RFLP or re-
verse hybridization to testing only samples from patients
with viral rebound (such as 5 log10 copies/ml or 4.3
log10 IU/ml) using less sensitive methods such as direct
sequencing (Table 3). These approaches result in reports
of LAM-associated resistance mutations after 1 year of
therapy varying from 7% to 23%.14,40 Figure 1 illustrates
mutations associated with approved HBV therapies.
(a) Resistance to Monotherapies
(i) Lamivudine and Other L-Nucleosides. The pri-
mary LAM resistance mutation maps to codon
rtM204V/I in the YMDD motif.12,41-43 In vitro studies
showed that these mutations decrease sensitivity to lami-
vudine by 100-fold (Table 3). The molecular mecha-
nism of LAM resistance is steric hindrance caused by the
-branched side group of the valine or isoleucine amino
acids colliding with the oxathiolane ring of LAM within
the dNTP binding site.38 The rtL180M is the main com-
pensatory change.12 Other compensatory mutations in-
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clude the rtV173L and rtL80I changes.9,17 The rtA181T
change has been reported to occur in the absence of
rtM204I/V and is considered a primary resistance muta-
tion.44,45 The rtA181T change is also selected during
ADV treatment.46 LAM-resistant mutations rtM204V/I
/ L180M decrease susceptibility to ETV.36,47
The primary LAM resistance mutations rtM204V/I
are cross-resistant with other L-nucleosides such as
emtricitabine (FTC), telbivudine (beta-L-thymidine,
LdT), beta-L-2-deoxycytidine (LdC), elvucitabine
and clevudine (L-FMAU; 2-fluoro-5-methyl-beta-L-ar-
abinofuranosyluracil), and the rtM204V/I changes have
been selected during treatment with these compounds
except for telbivudine where only rtM204I but not
rtM204V has been observed.7,48-51
Telbivudine is not active against HBV encoding
rtM204I or rtM204V  rtL180M in cell culture (www.
fda.gov). Lamivudine, telbivudine, and clevudine exhibit
modest activity against HBV encoding rtM204V alone in
cell culture52,53 but rtM204V mutation alone is rarely
detected in patients. Thus, neither clevudine nor telbivu-
dine is expected to be efficacious in patients with lamivu-
dine-resistant HBV.
(ii) Acyclic Phosphonates. Adefovir (ADV) — The
primary ADV-resistance mutations are rtN236T and /or
rtA181T/V.39,46,54 Isolates of HBV with the rtN236T
change are susceptible to LAM while isolates with
rtA181T/V changes have decreased susceptibility to LAM
(Table 3). These ADV-associated mutations result in only
a modest (2-9–fold) increase in EC50 but viral rebound,
hepatitis flares and hepatic decompensation have been
observed in patients.55 ADV-associated mutations are
partially cross-resistant with tenofovir. Decrease in serum
HBV DNA levels observed when patients with virologic
breakthrough due to ADV resistance are switched to te-
nofovir treatment is likely related to the higher dose of
tenofovir than adefovir (300 mg versus 10 mg) used in
clinical practice. The mechanism by which rtN236T con-
fer resistance to ADV is thought to be due to indirect
perturbation of the tri-phosphate binding site of the HBV
pol.38,54 Isolates of HBV with rtN236T and rtA181V
changes are susceptible to entecavir in vitro.39,48,56 Case
reports have confirmed the in vivo efficacy of lamivudine
and entecavir in the suppression of adefovir resistant
HBV.39,55,57
Tenofovir (TDF) — There was a recent report of resis-
tance to TDF associated with HBV encoding changes in
HBV polymerase at rtL180M  rtA194T (alanine to
threonine substitution)  rtM204V in 2 HIV / HBV
co-infected patients.58 HBV DNA was persistently de-
tected in these 2 patients during TDF and LAM therapy
but only 1 patient had an increase in serum HBV DNA.
Aminotransferase levels remained normal in both patients
and results of phenotypic studies are conflicting.59 Data
on TDF resistance in patients who received tenofovir
monotherapy are not available because tenofovir has been
used predominantly in patients with HIV/HBV coinfec-
tion, in combination with lamivudine or emtricitabine.
(iii) Entecavir. Two different ETV resistance geno-
typic profiles have been reported and confirmed in
vitro.47 The first pattern of ETV resistance includes:
rtI169T  rtL180M  rtM204V  rtM250V and the
second pattern includes: rtL180M  rtT184G 
rtS202I rtM204V (Table 3). Other patterns includ-
ing triple ETV-associated mutations have also been
Fig. 1. The hepatitis B virus (HBV) polymerase open reading frame
showing the conserved domains and location of the primary antiviral drug
resistance mutations within the conserved domains. Rt, reverse transcrip-
tion, LAM, lamivudine, ADV, adefovir dipivoxil, ETV, entecavir, LdT,
telbivudine.
Table 3. Rates of Antiviral-Resistant HBV Mutations







LAM 15-30% after 1 yr a b c
70% after 5 yr d
All pts PCR RFLP
ADV 0% after 1 yr e
29% after 5 yr f
All pts PCR Direct sequencing
LAM-R
pts
20% after 2 yr g h All pts PCR Line-probe,
MALDI-TOF
ETV 0% after 1 yr
1% after 2 & 3 yr i








LdT 2-3% after 1 yr k Pts with viral Direct sequencing
(LAM) 7-8% after 1 yr k rebound
Abbreviations: LAM-R, lamivudine resistance; pts, patients.
References: a Dienstag et al.75; b Lai et al. (1998)76; c Schalm et al.77; d Lok
et al.14; e Westland et al.78; f Hadziyannis et al.79; g Fung et al.57; h Lee et al.80;
i Colonno et al.62; j Colonno et al.81; k Lai et al. (2005).82
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observed.60 In the absence of the LAM-associated re-
sistance mutations, the rtM250V change causes a
9-fold increase in EC50 while the changes at rt 169
(I169T), 184 (T184A/F/G/I/L/S) or 202 (S202G/I)
changes have little effect (www.fda.gov). However, in
the presence of LAM-associated resistance mutations,
the ETV-associated mutations decrease susceptibility
to ETV by 100-fold, particularly when 2 or more
ETV-associated mutations are present.47 HBV isolates
with ETV-associated mutations are sensitive to adefo-
vir and tenofovir in vitro and in vivo data confirming
the efficacy of adefovir has been reported in one pa-
tient.61
Recent data suggest that pre-existence of mutations
such as rtL180M  rtM204V even when present in
0.1% of the viral population in patients who have not
received lamivudine treatment may increase the risk of
selection for ETV-associated mutations in patients receiv-
ing entecavir treatment.62 In addition, virologic break-
through may occur in nucleoside-naı̈ve patients
receiving entecavir treatment due to selection of LAM-
associated mutations alone. These data suggest that
resistance to entecavir occurs through a 2-hit mecha-
nism. Initially, LAM-associated mutants (rtM204V/I)
are selected because they are less sensitive to ETV than
wild type HBV. Virologic breakthrough usually occurs
only after emergence of additional ETV-associated
mutations, but rarely virologic breakthrough may oc-
cur after emergence of LAM-associated mutations
alone.62
(b) Multidrug Resistance
Sequential treatment with NA monotherapy has resulted
in the sequential selection of mutations conferring resistance
to the initial therapy and subsequently the rescue therapy.
For example, sequential resistance to lamivudine and later
adefovir has been reported in patients who were switched to
adefovir monotherapy for LAM-resistant HBV.60 Recent
studies reported that multidrug resistance changes can be
detected in patients who received sequential NA mono-
therapy and clonal analysis showed that in most instances,
the mutations associated with both treatments reside in the
same clone.56,60 The collocation of mutations associated
with resistance to different treatments on the same genome is
worrisome because in vitro analysis of antiviral sensitivities
revealed that replicating clones with LAM and ADV- asso-
ciated mutations had 50-fold reduced susceptibility to
combination of LAM and ADV indicating that combina-
tion therapy of the 2 drugs may not be effective in suppress-
ing multidrug resistant HBV.54,56
6. Monitoring and Treatment of Antiviral-
Resistant HBV
(a) Monitoring for Virologic Response and
Breakthrough
All patients receiving NA therapy for hepatitis B
should be closely monitored for virologic response and
breakthrough during treatment and for durability of re-
sponse and viral relapse after treatment has stopped. Se-
rum HBV DNA should be tested prior to treatment and
then every 3 months during treatment. Patients with pri-
mary nonresponse should be considered for alternative
treatment to facilitate clinical response and to minimize
subsequent antiviral resistance. Patients with virologic
breakthrough should be questioned about medication
compliance. Tests for antiviral-resistant mutations should
be performed whenever possible to confirm genotypic re-
sistance, and to determine the pattern of mutations. The
latter is particularly important as an increasing number of
patients have been exposed to more than one anti-HBV
NA.
(b) Treatment of Antiviral-Resistant HBV (Table 4)
Recommendations on treatment of patients with anti-
viral-resistant HBV depend on knowledge of the history
of HBV treatments, virologic response to these treat-
ments, the pattern of mutations detected at the time of
virologic breakthrough, and in vitro data on antiviral ac-
tivity of various HBV NAs against HBV isolates that har-
bor the mutations detected. Recent data suggest that
initiating rescue therapy when virologic breakthrough is
detected is more effective than delaying rescue therapy
until viral rebound or biochemical breakthrough.63
Table 4. Strategies for treating Antiviral-Resistant HBV
Type of Resistance Rescue Therapy
Lamivudine/telbivudine resistance ●Add adefovir or tenofovir
●Switch to emtricitabine  tenofovir
●Switch to entecavir (risk of subsequent
entecavir resistance and multidrug
resistance)
Adefovir resistance* ●Add lamivudine or switch to
emtricitabine  tenofovir
●Add entecavir (if no prior lamivudine
resistance)
Entecavir resistance* ●Add adefovir or tenofovir
Multidrug resistance# ●MDR to LAM  ADV: consider
tenofovir  emtricitabine, tenofovir
 entecavir
●MDR to LAM  ETV: consider tenofovir
or tenofovir  emtricitabine
Abbreviation: MDR, multidrug resistance.
*Limited in vivo data, available data indicate that addition of rescue therapy is
less likely to result in sequential drug resistance than switching to rescue therapy.
# In vivo data lacking
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(i) Lamivudine, Telbivudine and Other L-Nucleo-
side Resistance. In vitro studies have demonstrated that
adefovir, tenofovir, and entecavir have antiviral activity
against LAM- and other L-nucleoside-resistant HBV mu-
tants, but the activity of entecavir against these mutants is
substantially lower than for wild-type HBV (Table 3).36 A
pilot study in patients with lamivudine-resistant HBV
reported that adefovir monotherapy resulted in similar
rates of decrease in serum HBV DNA levels as combina-
tion therapy of lamivudine and adefovir.64 However,
combination of lamivudine and adefovir is more effective
in preventing subsequent adefovir resistance.57,65 Tenofo-
vir has also been reported in clinical studies to be effective
in suppressing lamivudine-resistant HBV.66,67 Although
tenofovir is more potent than adefovir, it is best used in
combination with lamivudine or emtricitabine to prevent
drug resistance. Entecavir has been shown in clinical trials
to be effective in suppressing lamivudine-resistant HBV
but a higher dose (1.0 mg daily) should be used.68 Pre-
existing LAM-resistant mutations increase the risk of en-
tecavir resistance47,62; therefore, entecavir is not an
optimal treatment for patients with lamivudine-resistant
HBV. If entecavir is used, lamivudine should be discon-
tinued.
Based on in vitro data and the detection of rtM204I in
patients with telbivudine resistance, the approach de-
scribed above can be applied to patients with telbivudine-
resistant HBV.
(ii) Adefovir. In vitro studies demonstrated that lami-
vudine and entecavir have antiviral activity against ADV-
resistant HBV mutants (Table 3).39,54 Case studies
confirmed that lamivudine is effective in suppressing se-
rum HBV DNA levels in patients with ADV-resistant
HBV.39,54 However, the durability of response, particu-
larly in patients with prior lamivudine resistance is un-
known. Furthermore, in the latter patients, a rapid re-
emergence of LAM-resistant mutations has been observed
on reintroduction of lamivudine.59,60 Case studies have
reported that patients with primary nonresponse to adefo-
vir experience further viral suppression when treatment is
switched to tenofovir69 presumably due to the higher dose
of tenofovir used in clinical practice. For the same reason,
tenofovir may result in some degree of viral suppression in
patients with ADV-resistant HBV but the efficacy is likely
limited due to in vitro evidence of cross resistance. Ente-
cavir has been reported to be efficacious in 2 patients with
ADV-resistant HBV.57
(iii) Entecavir. In vitro studies demonstrated that ad-
efovir and tenofovir have antiviral activity against ETV-
resistant HBV mutants47,48 (Table 2) but clinical data on
the efficacy of these treatments in patients with ETV-
resistant HBV are not yet available.
(iv) Multidrug-Resistant HBV. The most effective
treatment of multidrug-resistant HBV is prevention
through judicious use of NA therapy and avoidance of
sequential NA monotherapies. Thus, patients with mini-
mal disease and those who are unlikely to achieve sus-
tained response (such as inactive carriers and HBeAg-
positive patients in the immune tolerance phase) should
not be treated with NA therapy, particularly if they are
young. When possible, the most potent NA with the low-
est rate of genotypic resistance should be administered
and compliance reinforced. Response should be closely
monitored and modification of treatment considered in
patients with primary nonresponse. De novo combination
therapy of lamivudine plus pegylated interferon or adefo-
vir has been shown to be associated with lower rates of
virologic breakthrough compared to lamivudine mono-
therapy,70-72 but resistance was not completely prevented.
Studies on other de novo combination therapies are
needed to determine the optimal combination of drugs
and its cost-effectiveness.
7. Conclusions
Antiviral resistance and noncompliance to therapy are
the most important cause of treatment failure in patients
with hepatitis B. As more treatments become available,
the complexity of antiviral-resistant mutations and the
options for primary as well as rescue therapy increase.
Therefore, there is an urgent need for standardization of
(i) nomenclature on antiviral resistance, (ii) assays used in
detection or confirmation of resistance, and (iii) format
for reporting both in vitro and in vivo resistance data. This
document represents the collaborative efforts of investiga-
tors from North America, Europe, Asia, and Australia.
The group recognizes the importance of information
sharing not only among investigators but also between
investigators and practicing physicians such that new in-
formation generated from research can be rapidly dissem-
inated and observations in clinical practice can be
validated. To this end, the group hopes to establish a
database on hepatitis B virus drug resistance that will be
freely accessible and to develop means for sharing tech-
nology, clinical samples, and HBV isolates.
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